A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders

Gratacòs, Mónica; Soria, Virginia; Urretavizcaya, Mikel; González, Juan R.; Crespo, José Manuel; Bayés, Mònica; Cid, Rafael de; Menchón, José M.; Vallejo, Julio; Estivill, Xavier

doi:10.1038/sj.tpj.6500460

Cited by 80 publications

(60 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A similar heterosis effect was also reported for another SNP within BDNF (rs90887) [182]. Preliminary findings were provided for other BDNF SNPs (rs90887, rs61888800, rs7124442 and rs11030104) [179,182,183]. A strong association was established between rs962369 and an increase in suicidal ideation during antidepressant treatment [117].…”

Section: Brain-derived Neurotrophic Factor (Bdnf)supporting

confidence: 72%

See 1 more Smart Citation

Pharmacogenetics of antidepressant drugs: An update

Crisafulli¹,

Drago²,

Calabrò³

et al. 2014

Hosp Pharm Int Multi J

View full text Add to dashboard Cite

SUMMARYPharmacological treatment of depressive disorders is characterized by poor predictability of individual response. In recent years, the increasing evidence has demonstrated that genetic factors play a critical role in determining the differences in treatment outcome to antidepressant drugs. A number of pharmacogenetic studies on antidepressant drugs has been conducted, and genetic variations at level of drug metabolizing enzymes, drug transporters and drug targets, possibly influencing the clinical response, have been identified. Pharmacogenetics may hopefully provide the basis for individualized pharmacotherapy of depressive disorders in order to maximize the probability of a favorable response and minimize the risk of adverse drug reactions. In this article, the major findings related to the pharmacogenetics of genes involved in the pharmacokinetics and pharmacodynamics of antidepressant drugs are critically reviewed.

show abstract

Section: Brain-derived Neurotrophic Factor (Bdnf)supporting

confidence: 72%

“…Moreover, several negative findings were also found [180,181] in the large GENDEP sample [164]. A similar heterosis effect was also reported for another SNP within BDNF (rs90887) [182]. Preliminary findings were provided for other BDNF SNPs (rs90887, rs61888800, rs7124442 and rs11030104) [179,182,183].…”

Section: Brain-derived Neurotrophic Factor (Bdnf)supporting

confidence: 67%

Pharmacogenetics of antidepressant drugs: An update

Crisafulli¹,

Drago²,

Calabrò³

et al. 2014

Hosp Pharm Int Multi J

View full text Add to dashboard Cite

show abstract

“…18 No allelic differences among the individuals from the Spanish population were observed and the highest log likelihood scores were obtained when the number of populations was set to 1.…”

Section: Population Admixturementioning

confidence: 99%

Design and evaluation of a panel of single-nucleotide polymorphisms in microRNA genomic regions for association studies in human disease

Muiños‐Gimeno

Montfort²,

Bayés³

et al. 2009

Eur J Hum Genet

View full text Add to dashboard Cite

MicroRNAs (miRNA) are recognized posttranscriptional gene repressors involved in the control of almost every biological process. Allelic variants in these regions may be an important source of phenotypic diversity and contribute to disease susceptibility. We analyzed the genomic organization of 325 human miRNAs (release 7.1, miRBase) to construct a panel of 768 single-nucleotide polymorphisms (SNPs) covering B1 Mb of genomic DNA, including 131 isolated miRNAs (40%) and 194 miRNAs arranged in 48 miRNA clusters, as well as their 5-kb flanking regions. Of these miRNAs, 37% were inside known protein-coding genes, which were significantly associated with biological functions regarding neurological, psychological or nutritional disorders. SNP coverage analysis revealed a lower SNP density in miRNAs compared with the average of the genome, with only 24 SNPs located in the 325 miRNAs studied. Further genotyping of 340 unrelated Spanish individuals showed that more than half of the SNPs in miRNAs were either rare or monomorphic, in agreement with the reported selective constraint on human miRNAs. A comparison of the minor allele frequencies between Spanish and HapMap population samples confirmed the applicability of this SNP panel to the study of complex disorders among the Spanish population, and revealed two miRNA regions, hsa-mir-26a-2 in the CTDSP2 gene and hsa-mir-128-1 in the R3HDM1 gene, showing geographical allelic frequency variation among the four HapMap populations, probably because of differences in natural selection. The designed miRNA SNP panel could help to identify still hidden links between miRNAs and human disease.

show abstract

“…A functional variant at codon 66, resulting in a valanine to methionine change (Val66Met), is reported to correspond with drug response. Carriers of the Met allele were reported to have better treatment outcomes (Gratacos et al, 2008;Kato & Serretti, 2010), however, others did not find any correlation between the Val66Met variant and treatment response (Kato & Serretti, 2010;Tsai et al, 2003;Wilkie et al, 2007). Furthermore, genetic susceptibility to depression was not associated with the BDNF Val166Met variant (Gratacos et al, 2007;Lopez-Leon et al, 2008).…”

Section: Cellular and Molecular Markersmentioning

confidence: 96%